PubMed

The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

Waters D, Schwartz GG, Olsson AG.

Curr Control Trials Cardiovasc Med. 2001;2(3):111-114.PMID: 11806782 [PubMed - as supplied by publisher]Related articlesFree article

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.

Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T; MIRACL Study Investigators.

Circulation. 2002 Sep 24;106(13):1690-5.PMID: 12270864 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

Circulation. 2004 Jul 27;110(4):386-91. Epub 2004 Jul 19.PMID: 15262833 [PubMed - indexed for MEDLINE]Related articlesFree article

Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.

Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG.

Am J Cardiol. 1998 Mar 1;81(5):578-81.PMID: 9514453 [PubMed - indexed for MEDLINE]Related articles

The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice.

Aronow HD.

Curr Control Trials Cardiovasc Med. 2002 Jan 7;3(1):3.PMID: 11985777 [PubMed - as supplied by publisher]Related articlesFree article

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.PMID: 17910519 [PubMed - indexed for MEDLINE]Related articles

Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.

Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators.

J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96.PMID: 19497447 [PubMed - indexed for MEDLINE]Related articles

Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.

Schwartz GG, Olsson AG, Szarek M, Sasiela WJ.

Diabetes Care. 2005 Oct;28(10):2508-13.PMID: 16186288 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).

Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ.

Am J Cardiol. 2007 Mar 1;99(5):632-5. Epub 2007 Jan 9.PMID: 17317362 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

Arca M.

Drugs. 2007;67 Suppl 1:43-54. Review.PMID: 17910520 [PubMed - indexed for MEDLINE]Related articles

[Meeting report. "MIRACL" study of "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering"]

Scheen AJ.

Rev Med Liege. 2000 Dec;55(12):1064-6. French. PMID: 11205194 [PubMed - indexed for MEDLINE]Related articles

A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.

Buller N, Gillen D, Casciano R, Doyle J, Wilson K.

Pharmacoeconomics. 2003;21 Suppl 1:25-32.PMID: 12648032 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.

Gresser U, Gathof BS.

Eur J Med Res. 2004 Jan 26;9(1):1-17. Review.PMID: 14766335 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin: its clinical role in cerebrovascular prevention.

Gaspardone A, Arca M.

Drugs. 2007;67 Suppl 1:55-62. Review.PMID: 17910521 [PubMed - indexed for MEDLINE]Related articles

Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation.

Waters DD, Ku I.

J Am Coll Cardiol. 2009 Oct 6;54(15):1434-7.PMID: 19796736 [PubMed - indexed for MEDLINE]Related articles

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

JAMA. 2005 Nov 16;294(19):2437-45. Erratum in: JAMA. 2005 Dec 28;294(24):3092. PMID: 16287954 [PubMed - indexed for MEDLINE]Related articlesFree article

Early initiation of treatment with statins in acute coronary syndromes.

Olsson AG, Schwartz GG.

Ann Med. 2002;34(1):37-41. Review.PMID: 12014432 [PubMed - indexed for MEDLINE]Related articles

Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.

Rouleau J.

Am J Med. 2005 Dec;118 Suppl 12A:28-35.PMID: 16356805 [PubMed - indexed for MEDLINE]Related articles

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A.

Eur Heart J. 2005 May;26(9):890-6. Epub 2005 Mar 11.PMID: 15764620 [PubMed - indexed for MEDLINE]Related articlesFree article

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.

Lancet. 2006 Sep 9;368(9539):919-28.PMID: 16962881 [PubMed - indexed for MEDLINE]Related articles